As part of the joint study, Kantar Health will contribute the real-world study design and execution expertise to the project, while Nokia will leverage its world-class technology assets to generate biometric data and facilitate study delivery.
The first data analysis of research findings is expected by the Fall of 2017. Final research findings will be completed and announced by the Spring of 2018. Data from the research will be made available to the industry for purchase.
“As the role of the patient continues to evolve, management of chronic conditions such as diabetes is transforming through the ever increasing use of connected devices in patient populations,” said Geneviève Bonnelye, Managing Director, Kantar Health in a statement. “Lifestyle therapy, including changes in nutrition, physical activity, sleep and nicotine use, is an essential component of type 2 diabetes treatment, however there’s a lack of longitudinal patient data about the disease’s impact on weight, activity level, sleep and blood pressure, as well as limited evidence on how treatment management is affecting patients’ loss or gain of weight. There’s a clear need for a solution that combines attitudinal and evidence-based data, helps manage weight and links treatment management and HBA1C results. Our landmark study with Nokia should help fill these data gaps and ultimately improve patient care.”